Literature DB >> 29888533

The CATCH checklist to investigate adult-onset hypogonadism.

G Defeudis1,2, R Mazzilli1, D Gianfrilli1, A Lenzi1, A M Isidori1.   

Abstract

Adult-onset hypogonadism is a syndrome often underdiagnosed, undertreated, or incompletely explored. There are various reasons for this: firstly, undefined age range of men in whom testosterone levels should be investigated and then no definitive serum cutoff point for the diagnosis of hypogonadism; and finally, variable and non-specific signs and symptoms; men and physicians do not pay adequate attention to sexual health. All these factors make the diagnostic criteria for hypogonadism controversial. The evaluation of the clinical features and causes of this syndrome, its link with age, the role of testosterone and other hormone levels, and the presence of any comorbidities are all useful factors in the investigation of this population. The purpose of this manuscript, after an accurate analysis of current literature, is to facilitate the diagnosis of hypogonadism in men through the use of the CATCH acronym and a checklist to offer a practical diagnostic tool for daily clinical practice. A narrative review of the relevant literature regarding the diagnosis of late-onset hypogonadism or adult-onset hypogonadism was performed. PubMed database was used to retrieve articles published on this topic. A useful new acronym CATCH (Clinical features [symptoms] and Causes, Age, Testosterone level, Comorbidities, and Hormones) and a practical checklist to facilitate the evaluation of hypogonadism in aging men were used. The evaluation of the clinical features and causes of hypogonadism, the link with age, the role of Testosterone and other hormones, and the evaluation of comorbidities are important in investigating adult-onset hypogonadism. The CATCH checklist could be helpful for clinicians for an early diagnosis of both hypogonadism and associated comorbidities. We suggest the use of this acronym to advocate the investigation of declining testosterone in aging men.
© 2018 American Society of Andrology and European Academy of Andrology.

Entities:  

Keywords:  checklist; erectile dysfunction; hypogonadism; sexual dysfunction

Mesh:

Substances:

Year:  2018        PMID: 29888533     DOI: 10.1111/andr.12506

Source DB:  PubMed          Journal:  Andrology        ISSN: 2047-2919            Impact factor:   3.842


  11 in total

1.  Bone and body composition response to testosterone therapy vary according to polymorphisms in the CYP19A1 gene.

Authors:  Lina E Aguirre; Georgia Colleluori; David Robbins; Richard Dorin; Vallabh O Shah; Rui Chen; Irum Zeb Jan; Clifford Qualls; Dennis T Villareal; Reina Armamento-Villareal
Journal:  Endocrine       Date:  2019-07-19       Impact factor: 3.633

Review 2.  The role of testosterone in men's health: is it time for a new approach?

Authors:  Ananias C Diokno
Journal:  Int Urol Nephrol       Date:  2022-08-01       Impact factor: 2.266

Review 3.  The role of thyroid function in female and male infertility: a narrative review.

Authors:  S La Vignera; G Defeudis; R Mazzilli; S Medenica; A M Di Tommaso; G Fabozzi; V Zamponi; D Cimadomo; L Rienzi; F M Ubaldi; M Watanabe; A Faggiano
Journal:  J Endocrinol Invest       Date:  2022-08-09       Impact factor: 5.467

Review 4.  Erectile dysfunction and diabetes: A melting pot of circumstances and treatments.

Authors:  Giuseppe Defeudis; Rossella Mazzilli; Marta Tenuta; Giovanni Rossini; Virginia Zamponi; Soraya Olana; Antongiulio Faggiano; Paolo Pozzilli; Andrea M Isidori; Daniele Gianfrilli
Journal:  Diabetes Metab Res Rev       Date:  2021-09-21       Impact factor: 8.128

5.  Borderline-low testosterone levels are associated with lower left ventricular wall thickness in firefighters: An exploratory analysis.

Authors:  Adriana Lofrano-Porto; Edgard M K V K Soares; Alexs Matias; Luiz Guilherme Grossi Porto; Denise L Smith
Journal:  Andrology       Date:  2020-09-03       Impact factor: 3.842

Review 6.  Burden of Male Hypogonadism and Major Comorbidities, and the Clinical, Economic, and Humanistic Benefits of Testosterone Therapy: A Narrative Review.

Authors:  Sandy Yeo; Katsiaryna Holl; Nicolás Peñaherrera; Ulrike Wissinger; Kate Anstee; Robin Wyn
Journal:  Clinicoecon Outcomes Res       Date:  2021-01-12

7.  Rapid Changes in Serum Testosterone in Men With Newly Diagnosed Type 2 Diabetes With Intensive Insulin and Metformin.

Authors:  Yun Hu; Bo Ding; Yun Shen; Reng-Na Yan; Feng-Fei Li; Rui Sun; Ting Jing; Kok-Onn Lee; Jian-Hua Ma
Journal:  Diabetes Care       Date:  2021-02-03       Impact factor: 19.112

8.  Short-time intensive insulin therapy upregulates 3 beta- and 17 beta-hydroxysteroid dehydrogenase levels in men with newly diagnosed T2DM.

Authors:  Yun Hu; Ying Wang; Ting-Ting Cai; Lu Liu; Dong-Mei Li; Jian-Hua Ma; Bo Ding
Journal:  Front Endocrinol (Lausanne)       Date:  2022-07-19       Impact factor: 6.055

9.  Genetic Susceptibility for Low Testosterone in Men and Its Implications in Biology and Screening: Data from the UK Biobank.

Authors:  Richard J Fantus; Rong Na; Jun Wei; Zhuqing Shi; W Kyle Resurreccion; Joshua A Halpern; Omar Franco; Simon W Hayward; William B Isaacs; S Lilly Zheng; Jianfeng Xu; Brian T Helfand
Journal:  Eur Urol Open Sci       Date:  2021-05-25

Review 10.  Severe male factor in in vitro fertilization: definition, prevalence, and treatment. An update.

Authors:  Rossella Mazzilli; Alberto Vaiarelli; Lisa Dovere; Danilo Cimadomo; Nicolò Ubaldi; Susanna Ferrero; Laura Rienzi; Francesco Lombardo; Andrea Lenzi; Herman Tournaye; Filippo Maria Ubaldi
Journal:  Asian J Androl       Date:  2022 Mar-Apr       Impact factor: 3.285

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.